Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/21/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/15/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/15/25 | 3 | Initial statement of beneficial ownership of securities |
|
4 |
